Alpha1-proteinase inhibitor human parenteral
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Infusions of alpha1-proteinase inhibitor human.
Emphysema associated with alpha-1-antitrypsin deficiency
Maintenance treatment to slow the progression of emphysema in adults with documented severe alpha 1-proteinase inhibitor deficiency, despite optimal treatment with other standard therapies.
60mg/kg body weight administered once a week.
Children under 18 years
Immunoglobulin A deficiency with IgA antibodies
Precautions and Warnings
Patients over 65 years
Restricted sodium intake
Contains more than 1 mmol (23 mg) sodium per dose
Advise ability to drive/operate machinery may be affected by side effects
Treatment to be initiated and supervised by a specialist
Derived from human plasma. Transmission of infective agents possible.
Do not mix with other drugs or substances
For single use only
Must be given as an intravenous infusion
Record name and batch number of administered product
Vaccinate patients receiving this product against hepatitis A and B
Monitor vital signs during initial stage of infusion
Advise patient to report symptoms of allergic type hypersensitivity
Consider discontinuing if suspected allergic reaction occurs
Interrupt therapy/reduce infusion rate if infusion-related reactions occur
Management of cases of shock should follow current medical standards
Advise patient on giving up smoking
During the first infusions, patient's clinical state, including vital signs, should be closely monitored throughout the infusion period. If any reaction takes place that might be related to the administration of human alpha 1-proteinase inhibitor, the rate of infusion should be decreased or the administration should be stopped, as required by the clinical condition of the patient. If symptoms subside promptly after stopping, the infusion may be resumed at a lower rate that is comfortable for the patient.
Standard safety measures to prevent infections resulting from the use of medicinal agents prepared from human blood or plasma include rigorous selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation and removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.
Pregnancy and Lactation
Use alpha1-proteinase inhibitor human with caution during pregnancy.
The manufacturer advises caution if alpha 1-proteinase inhibitor is used during pregnancy. Although there have been no studies in animal reproduction, as alpha1-proteinase inhibitor is an endogenous human protein, when given at the recommended dose it is unlikely to cause harm to the foetus.
Alpha1-proteinase inhibitor human is contraindicated in breastfeeding.
It is not known if alpha1-proteinase inhibitor human is excreted in human milk. The excretion of this agent has not been studied in animals. The manufacturer notes that a decision must be made whether to discontinue breastfeeding or to discontinue the therapy, taking into account the benefit of breastfeeding for the child and the benefit of the therapy for the woman.
Injection site reactions
Lymph node pain
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: March 2020.
Summary of Product Characteristics: Respreeza 1,000 mg powder and solvent for solution for infusion. CSL Behring UK Limited. October 2018.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.